Effect of fish oil on arrhythmias and mortality: systematic review

• Author(s) / Creator(s)

  • Leon, H.
  • Tsuyuki, R.T.
  • Dorgan, M.
  • Chatterley, T.
  • Sivakumaran, S.
  • Shibata, M.C.

• Abstract: Objective To synthesise the literature on the effects of fish oil - docosahexaenoic acid ( DHA) and eicosapentaenoic acid ( EPA) - on mortality and arrhythmias and to explore dose response and formulation effects. Design Systematic review and meta- analysis. Data sources Medline, Embase, the Cochrane Library, PubMed, CINAHL, IPA, Web of Science, Scopus, Pascal, Allied and Complementary Medicine, Academic OneFile, ProQuest Dissertations and Theses, Evidence- Based Complementary Medicine, and LILACS. Studies reviewed Randomised controlled trials of fish oil as dietary supplements in humans. Data extraction The primary outcomes of interest were the arrhythmic end points of appropriate implantable cardiac defibrillator intervention and sudden cardiac death. The secondary outcomes were all cause mortality and death from cardiac causes. Subgroup analyses included the effect of formulations of EPA and DHA on death from cardiac causes and effects of fish oil in patients with coronary artery disease or myocardial infarction. Data synthesis 12 studies totalling 32 779 patientsmet the inclusion criteria. A neutral effect was reported in three studies ( n= 1148) for appropriate implantable cardiac defibrillator intervention ( odds ratio 0.90, 95% confidence interval 0.55 to 1.46) and in six studies ( n= 31 111) for sudden cardiac death ( 0.81, 0.52 to 1.25). 11 studies ( n= 32 439 and n= 32 519) provided data on the effects of fish oil on all cause mortality ( 0.92, 0.82 to 1.03) and a reduction in deaths from cardiac causes ( 0.80, 0.69 to 0.92). The dose- response relation for DHA and EPA on reduction indeaths from cardiac causes was not significant. Conclusions Fish oil supplementation was associated with a significant reduction in deaths from cardiac causes but had no effect on arrhythmias or all cause mortality. Evidence to recommend an optimal formulation of EPA or DHA to reduce these outcomes is insufficient. Fish oils are a heterogeneous product, and the optimal formulations for DHA and EPA remain unclear.

• Date created

  2008

• Subjects / Keywords

  • Double blind
  • Polyunsaturated fatty-acids
  • Cardiovascular diseases
  • Acute myocardial infarction
  • Omega-3 fatty acids
  • Meta-analysis
  • Coronary heart disease
  • Randomized controlled trials
  • Premature ventricular complexes
  • Sudden cardiac death

• Type of Item

  Review

• DOI

  https://doi.org/10.7939/R3N58CN8F

• License

  Attribution-NonCommercial 3.0 International